IN THIS ISSUE

Q&A
John Marcille
The UC–Berkeley health care economist says the cost-control and performance-improvement methods we’ve been developing for years can work, but implementing them on a wide scale may come as a last resort
John Carroll
Provenge is just one example of an expensive biotechnology drug whose survival analyses leave much to be desired
Frank Diamond
Treating sleep apnea greatly reduces global costs, but compliance remains a concern
Editor's Memo
John Marcille
Brad Wilson

Brad Wilson

By segmenting services, employers limit their ability to leverage powerful data analyses that drive health improvement and cost reduction.

Legislation & Regulation
John Carroll
Health plan officials are not doing handstands over the federal government’s extension of a deadline to disclose benefits to members in a readable form
Medication Management
Thomas Reinke
Insurers feel pressure to incorporate new agents into their drug benefit, but evidence of effectiveness is questionable
Evidence Review
A summary of ECRI Institute’s Health Technology Forecast Report
Snapshot
Frank Diamond
Employers and the federal government like these programs, but some question their cost-effectiveness
Tomorrow's Medicine
Thomas Morrow, MD
There are many genetic mutations attributable to the condition, but Kalydeco can significantly help a specific subpopulation of patients
News & Commentary
News & Commentary